Shares of AIM ImmunoTech Inc. (NYSE American: AIM) rocketed higher Wednesday, closing at $1.02, up 31 cents or 43.66%, on extraordinarily heavy trading volume exceeding 183 million shares as investors ...

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...

Scientists recently confirmed that a variation of the avian influenza virus is responsible for sea bird deaths in Antarctica.

DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, ...

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

Correspondence to Dr Bionka M A Huisstede, Department of Rehabilitation, Erasmus MC—University Medical Center Rotterdam, Room H-016, PO Box 2040, Rotterdam 3000 CA, The Netherlands; ...

Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26 ...

Autism diagnostic specialist BlinkLab (ASX: BB1) has entered into a new partnership with the US-based SHANK2 foundation. Listen to the HotCopper podcast for in-depth discussions and insights on all ...